Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Tofacitinib Is Safe According to Real-world Data Analysis

Tofacitinib Is Safe According to Real-world Data Analysis

Presented By
Dr Joel Kremer, Albany Medical College, New York, USA
Conference
EULAR 2019

Tofacitinib, a Janus kinase (JAK)1/3 inhibitor had a safety profile similar to that of biologics. Rheumatoid arthritis (RA) patients starting with tofacitinib or biological disease-modifying anti-rheumatic drugs (bDMARDs) had similar rates of cardiovascular events and serious infections. These are the main findings obtained after a prospective 5-year cohort study of >8,600 RA patients enrolled in a US national registry.

This is the first comparative real-world data study assessing long-term safety of tofacitinib which is an important consideration given the cardiovascular safety of anti-TNF agents. Dr Joel Kremer (Albany Medical College, New York, USA) et al. evaluated 5-year adverse event incidence rates in patients starting tofacitinib versus bDMARDs using cohorts from the US Corrona RA registry, during November 2012, the month when tofacitinib received US marketing approval, through December 2017 [1].

Data were obtained from RA patients in the...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on